|
1.
|
Hazra S, Peebles KA, Sharma S, Mao JT and
Dubinett SM: The role of PPARgamma in the cyclooxygenase pathway in
lung cancer. PPAR Res. 2008:7905682008. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Vijayalakshmi R and Krishnamurthy A:
Targetable “driver” mutations in non small cell lung cancer. Indian
J Surg Oncol. 2:178–188. 2011.
|
|
3.
|
Yuan SF, Chen WJ, Zhu LJ, Zheng WE, Chen H
and Xiong JP: Effects of monoclonal antibodies against human
stathmin combined with paclitaxel on proliferation of the QG-56
human lung carcinoma cell line. Asian Pac J Cancer Prev.
13:2967–2971. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Kuo PL, Hsu YL, Ng LT and Lin CC: Rhein
inhibits the growth and induces the apoptosis of Hep G2 cells.
Planta Med. 70:12–16. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Huang Q, Lu G, Shen HM, Chung MC and Ong
CN: Anti-cancer properties of anthraquinones from rhubarb. Med Res
Rev. 27:609–630. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Lai WW, Yang JS, Lai KC, et al: Rhein
induced apoptosis through the endoplasmic reticulum stress,
caspase-and mitochondria-dependent pathways in SCC-4 human tongue
squamous cancer cells. In Vivo. 23:309–316. 2009.
|
|
7.
|
Ip SW, Weng YS, Lin SY, et al: The role of
Ca2+ on rhein-induced apoptosis in human cervical cancer
Ca Ski cells. Anticancer Res. 27:379–389. 2007.
|
|
8.
|
Lin ML, Chen SS, Lu YC, et al: Rhein
induces apoptosis through induction of endoplasmic reticulum stress
and Ca2+-dependent mitochondrial death pathway in human
nasopharyngeal carcinoma cells. Anticancer Res. 27:3313–3322.
2007.PubMed/NCBI
|
|
9.
|
Cichewicz RH, Zhang Y, Seeram NP and Nair
MG: Inhibition of human tumor cell proliferation by novel
anthraquinones from daylilies. Life Sci. 74:1791–1799. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Floridi A, Gentile PF, Bruno T, et al:
Cytotoxic effect of the association of BCNU with rhein or
lonidamine on a human glioma cell line. Anticancer Res. 11:789–792.
1991.PubMed/NCBI
|
|
11.
|
Lin YJ and Zhen YS: Rhein lysinate
suppresses the growth of breast cancer cells and potentiates the
inhibitory effect of Taxol in athymic mice. Anticancer Drugs.
20:65–72. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Lin YJ, Zhen YZ, Shang BY and Zhen YS:
Rhein lysinate suppresses the growth of tumor cells and increases
the anti-tumor activity of Taxol in mice. Am J Chin Med.
37:923–931. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Lin YJ, Huang YH, Zhen YZ, Liu XJ and Zhen
YS: Rhein lysinate induces apoptosis in breast cancer SK-Br-3 cells
by inhibiting HER-2 signal pathway. Yao Xue Xue Bao. 43:1099–1105.
2008.(In Chinese).
|
|
14.
|
Zhen YZ, Lin YJ, Gao JL, Zhao YF and Xu
AJ: Rhein lysinate inhibits cell growth by modulating various
mitogen-activated protein kinases in cervical cancer cells. Oncol
Lett. 2:129–133. 2011.PubMed/NCBI
|
|
15.
|
Brognard J and Dennis PA: Variable
apoptotic response of NSCLC cells to inhibition of the MEK/ERK
pathway by small molecules or dominant negative mutants. Cell Death
Differ. 9:893–904. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Lee MW, Kim DS, Min NY and Kim HT: Akt1
inhibition by RNA interference sensitizes human non-small cell lung
cancer cells to cisplatin. Int J Cancer. 122:2380–2384. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Ozaki K, Kosugi M, Baba N, et al: Blockade
of the ERK or PI3K-Akt signaling pathway enhances the cytotoxicity
of histone deacetylase inhibitors in tumor cells resistant to
gefitinib or imatinib. Biochem Biophys Res Commun. 391:1610–1615.
2010. View Article : Google Scholar
|
|
18.
|
Lunghi P, Giuliani N, Mazzera L, et al:
Targeting MEK/MAPK signal transduction module potentiates
ATO-induced apoptosis in multiple myeloma cells through multiple
signaling pathways. Blood. 112:2450–2462. 2008. View Article : Google Scholar
|
|
19.
|
Enari M, Sakahira H, Yokoyama H, Okawa K,
Iwamatsu A and Nagata S: A caspase-activated DNase that degrades
DNA during apoptosis, and its inhibitor ICAD. Nature. 391:43–50.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Wolf BB, Schuler M, Echeverri F and Green
DR: Caspase-3 is the primary activator of apoptotic DNA
fragmentation via DNA fragmentation factor-45/inhibitor of
caspase-activated DNase inactivation. J Biol Chem. 274:30651–30656.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Fan TJ, Han LH, Cong RS and Liang J:
Caspase family proteases and apoptosis. Acta Biochim Biophys Sin
(Shanghai). 37:719–727. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
McDonnell TJ, Beham A, Sarkiss M, Andersen
MM and Lo P: Importance of the Bcl-2 family in cell death
regulation. Experientia. 52:1008–1017. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Reed JC, Miyashita T, Takayama S, et al:
BCL-2 family proteins: regulators of cell death involved in the
pathogenesis of cancer and resistance to therapy. J Cell Biochem.
60:23–32. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Halasova E, Adamkov M, Matakova T, et al:
Expression of Ki-67, Bcl-2, Survivin and p53 Proteins in Patients
with Pulmonary Carcinoma. Adv Exp Med Biol. 756:15–21. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Arlt A, Gehrz A, Müerköster S, et al: Role
of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma
cell lines against gemcitabine-induced cell death. Oncogene.
22:3243–3251. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Linardopoulos S: Aurora-A kinase regulates
NF-kappaB activity: lessons from combination studies. J BUON.
12(Suppl 1): S67–S70. 2007.PubMed/NCBI
|
|
27.
|
Deng LL, Shao YX, Lv HF, Deng HB and Lv
FZ: Over-expressing CYLD augments antitumor activity of TRAIL by
inhibiting the NF-κB survival signaling in lung cancer cells.
Neoplasma. 59:18–29. 2012.PubMed/NCBI
|
